Latest Organogenesis Inc. Stories

2014-08-04 08:27:45

Access to Apligraf® is Improved for Veterans with Chronic Diabetic Foot Ulcers and Venous Leg Ulcers CANTON, Mass., Aug 4, 2014 /PRNewswire/ -- Organogenesis Inc. announced today that it has been awarded Federal Supply Schedule Contract V797D-30288 with the Department of Veterans Affairs (VA) for Apligraf®, the only product with FDA approval for the treatment of both diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). This five-year contract includes an option to extend its...

2014-05-20 16:23:32

MARIETTA, Ga., May 20, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today it has declined to participate in the adjudication of an advertising challenge filed with the National Advertising Division of the Council of Better Business Bureaus (NAD). The NAD administers a self-regulation program designed to ensure the...

2014-04-22 12:31:27

CANTON, Mass. and ORLANDO, Fla., April 22, 2014 /PRNewswire/ -- This week, Organogenesis Inc. will present new mechanisms of action data from an Apligraf(®) clinical study and in vitro / pre-clinical data evaluating mechanisms of healing for Dermagraft(®) at the Symposium on Advanced Wound Care (SAWC) / Wound Healing Society (WHS) Spring 2014 meeting in Orlando, Fla. Additionally, Organogenesis will feature both Apligraf and Dermagraft at booth #709. "There is more than a decade of...

2014-02-04 04:21:50

DUBLIN, February 4, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today releases historical income statements on both a US GAAP and Non GAAP basis for 2012 and the nine months ended September 30, 2013, recast to show the impact of DERMAGRAFT operations as discontinued. On January 17, 2014 Shire announced that it had entered into a definitive agreement pursuant to which it has sold certain of its DERMAGRAFT...

2014-01-17 08:23:07

Product Acquisition Solidifies Organogenesis Position as Industry Leader CANTON, Mass., Jan. 17, 2014 /PRNewswire/ -- Organogenesis Inc., a commercial leader in the field of regenerative medicine, announced today that it has purchased the Dermagraft® assets (human fibroblast-derived dermal substitute) from Shire plc (LSE: SHP, NASDAQ: SHPG). "Organogenesis is a pioneering company in the regenerative medicine and wound healing fields, and we are now the proud owners of two products...

2014-01-09 12:27:35

LONDON, Jan. 9, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Bioactive Wound Care Market in the US 2012-2016 TechNavio's analysts forecast the Bioactive Wound Care market in the US to grow at a CAGR of 5.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in elderly population in the US. The Bioactive Wound Care market in the US has also been witnessing an increasing adoption of...

Word of the Day
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.